Literature DB >> 363945

Antigen-induced murine B cell lymphomas. I. Induction and characterization of CH1 and CH2.

M A Lynes, L L Lanier, G F Babcock, P J Wettstein, G Haughton.   

Abstract

Two unusual murine lymphomas, designated CH1 and CH2, were produced in the newly developed double congenic strain of mice, B10 H-2a H-4b p/Wts. Both tumors lack the T cell-specific antigen (thy-1), but express cell surface immunoglobulin and the H-2K, H-2D, and Ia specificities determined by the H-2a haplotype. Further studies have demonstrated that these tumors represent "early" B cells in that they express surface IgM (mu heavy and lambda light chains), but do not bear surface delta, gamma, or alpha heavy chains. CH1 and CH2 lack surface C3 receptors and results from assays for Fc receptors have proven variable. A competition radioimmunoassay directed against the gp71 group-specific antigen of Friend leukemia virus has shown that there is a murine leukemia virus associated with these tumors, however, we have been unable to establish a causal relationship between the virus and this malignancy. A comparison of the surface characteristics of these tumors with other mammalian B cell lymphomas is presented.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 363945

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Immunoglobulin gene 'remnant' DNA--implications for antibody gene recombination.

Authors:  E Selsing; J Voss; U Storb
Journal:  Nucleic Acids Res       Date:  1984-05-25       Impact factor: 16.971

2.  Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin.

Authors:  K A Krolick; C Villemez; P Isakson; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

3.  Transplantable B-cell lymphomas in B10. H-2aH-4bp/Wts mice.

Authors:  L L Lanier; L W Arnold; R B Raybourne; S Russell; M A Lynes; N L Warner; G Haughton
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

4.  Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells.

Authors:  Z Razi-Wolf; G J Freeman; F Galvin; B Benacerraf; L Nadler; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

5.  Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer.

Authors:  A Muto; H Hoshino; L Madisen; N Yanai; M Obinata; H Karasuyama; N Hayashi; H Nakauchi; M Yamamoto; M Groudine; K Igarashi
Journal:  EMBO J       Date:  1998-10-01       Impact factor: 11.598

6.  Ets factors and a newly identified polymorphism regulate Fli1 promoter activity in lymphocytes.

Authors:  Tamara K Nowling; Jennifer Dziadyk Fulton; Katherine Chike-Harris; Gary S Gilkeson
Journal:  Mol Immunol       Date:  2007-07-02       Impact factor: 4.407

7.  The mouse E beta 2 gene: a class II MHC beta gene with limited intraspecies polymorphism and an unusual pattern of transcription.

Authors:  N S Braunstein; R N Germain
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

8.  Regulation of MHC class II invariant chain expression: induction of synthesis in human and murine plasmocytoma cells by arresting replication.

Authors:  H J Rahmsdorf; N Koch; U Mallick; P Herrlich
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

9.  Germinal center initiation, variable gene region hypermutation, and mutant B cell selection without detectable immune complexes on follicular dendritic cells.

Authors:  L G Hannum; A M Haberman; S M Anderson; M J Shlomchik
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  The B cell receptor itself can activate complement to provide the complement receptor 1/2 ligand required to enhance B cell immune responses in vivo.

Authors:  Joerg Rossbacher; Mark J Shlomchik
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.